Drug
Adagrasib Dose OF Twice Daily
Adagrasib Dose OF Twice Daily: highest development phase Phase 2, developed by Mirati Therapeutics. 1 trial record tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- Mirati Therapeutics
Trials
| Drug | Phase | Indication |
|---|---|---|
| Adagrasib oral dose of 400 mg twice daily tablets NCT05609578 | Phase 2 | Advanced NSCLC |
Latest
No recent events.
Follow Adagrasib Dose OF Twice Daily on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.